@article{ref1,
title="Ecstasy: pharmacodynamic and pharmacokinetic interactions",
journal="Psychosomatics",
year="2004",
author="Oesterheld, Jessica R. and Armstrong, Scott C. and Cozza, Kelly L.",
volume="45",
number="1",
pages="84-87",
abstract="At &quot;raves,&quot; young people dance and ingest illicit drugs, the most common of which is MDMA (N-methyl-3,4,-methylenedioxymethamphetamine) or &quot;ecstasy.&quot; This drug is metabolized principally through the cytochrome P450 (CYP450) 2D6 enzyme. Pharmacokinetic drug-drug interactions can occur if MDMA is combined with other recreational or therapeutic drugs that are 2D6 inhibitors. Ecstasy concentration may increase to cause toxicity. Since ecstasy is pro-serotonergic, it may also be involved in pharmacodynamic drug-drug interactions when other pro-serotonergic drugs are combined with it, leading to a central serotonin syndrome. Some drugs are both pro-serotonergic and CYP450 2D6 inhibitors and, if co-administered with ecstasy, may cause both pharmacokinetic and pharmacodynamic drug-drug interactions.<p /><p>Language: en</p>",
language="en",
issn="0033-3182",
doi="10.1176/appi.psy.45.1.84",
url="http://dx.doi.org/10.1176/appi.psy.45.1.84"
}